心脏结节病需要植入植入式心脏复律除颤器，以及在使用阿仑单抗治疗多发性硬化症后出现免疫性血小板减少症。
Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis.
作者信息
Erlich-Malona Natalie, Cahill Jonathan, Chaudhry Saima, Martin Janice, Rizvi Syed
机构信息
Brown University Department of Neurology, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA.
Brown University Department of Neurology, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA.
出版信息
Mult Scler Relat Disord. 2021 Jan;47:102599. doi: 10.1016/j.msard.2020.102599. Epub 2020 Oct 28.
Alemtuzumab, an effective disease-modifying therapy for multiple sclerosis, carries a significant risk of secondary autoimmunity. We present a case of cardiac sarcoidosis and immune thrombocytopenia diagnosed in an MS patient two years after completing alemtuzumab treatment. We hypothesize that alemtuzumab-induced changes to the T regulatory cell population may be implicated in the development of sarcoidosis in MS patients.
阿仑单抗是一种治疗多发性硬化症的有效疾病修正疗法，但具有引发继发性自身免疫的重大风险。我们报告了一例在完成阿仑单抗治疗两年后被诊断出患有心脏结节病和免疫性血小板减少症的多发性硬化症患者。我们推测，阿仑单抗引起的调节性T细胞群体变化可能与多发性硬化症患者结节病的发生有关。
Zotero 插件